Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HCP1105 vs HGP0918 + HGP0816 in Healthy Males
NCT02941796Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of HCP1105 in hyperlipidemia (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Baseline-corrected Cmax of DHA total lipid & EPA total lipid up to 72 hours, Baseline-corrected AUCt of DHA total lipid & EPA total lipid up to 72 hours and 2 more. Started Jun 2016; status: completed.
02
Drugs
HCP1105
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02941796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02941796.